Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Hiroyuki Tsutsui; Nancy M Albert; Andrew J S Coats; Stefan D Anker; Antoni Bayes-Genis; Javed Butler; Ovidiu Chioncel; Christopher R Defilippi; Mark H Drazner; G Michael Felker; Gerasimos Filippatos; Mona Fiuzat; Tomomi Ide; James L Januzzi Jr; Koichiro Kinugawa; Koichiro Kuwahara; Yuya Matsue; Robert J Mentz; Marco Metra; Ambarish Pandey; Giuseppe Rosano; Yoshihiko Saito; Yasushi Sakata; Naoki Sato; Petar M Seferovic; John Teerlink; Kazuhiro Yamamoto; Michihiro Yoshimura

doi:10.1016/j.cardfail.2023.02.009

Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

J Card Fail. 2023 May;29(5):787-804. doi: 10.1016/j.cardfail.2023.02.009. Epub 2023 Apr 17.

Authors

Hiroyuki Tsutsui¹, Nancy M Albert², Andrew J S Coats³, Stefan D Anker⁴, Antoni Bayes-Genis⁵, Javed Butler⁶, Ovidiu Chioncel⁷, Christopher R Defilippi⁸, Mark H Drazner⁹, G Michael Felker¹⁰, Gerasimos Filippatos¹¹, Mona Fiuzat¹⁰, Tomomi Ide¹², James L Januzzi Jr¹³, Koichiro Kinugawa¹⁴, Koichiro Kuwahara¹⁵, Yuya Matsue¹⁶, Robert J Mentz¹⁷, Marco Metra¹⁸, Ambarish Pandey¹⁹, Giuseppe Rosano²⁰, Yoshihiko Saito²¹, Yasushi Sakata²², Naoki Sato²³, Petar M Seferovic²⁴, John Teerlink²⁵, Kazuhiro Yamamoto²⁶, Michihiro Yoshimura²⁷

Affiliations

¹ Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: [email protected].
² Research and Innovation-Nursing Institute, Kaufman Center for Heart Failure-Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
³ University of Warwick, Warwick, UK, and Monash University, Clayton, Australia.
⁴ Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies; German Centre for Cardiovascular Research partner site Berlin, Germany; Charité Universitätsmedizin Berlin, Germany; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
⁵ Heart Institute, Hospital Germans Trias i Pujol, CIBERCV, Badalona, Spain; Universitat Autonoma Barcelona, Spain.
⁶ Baylor Scott and White Research Institute, Dallas, Texas, USA; University of Mississippi, Jackson, Mississippi, USA.
⁷ Emergency Institute for Cardiovascular Diseases Prof. C.C. Iliescu Bucharest, University of Medicine Carol Davila, Bucharest, Romania.
⁸ Inova Heart and Vascular Institute, Falls Church, Virginia, USA.
⁹ Clinical Chief of Cardiology, University of Texas Southwestern Medical Center, Department of Internal Medicine/Division of Cardiology, Dallas, Texas, USA.
¹⁰ Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.
¹¹ School of Medicine of National and Kapodistrian University of Athens, Athens University Hospital Attikon, Athens, Greece.
¹² Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
¹³ Massachusetts General Hospital, Harvard Medical School and Baim Institute for Clinical Research, Boston, Massachusetts, USA.
¹⁴ Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
¹⁵ Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
¹⁶ Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
¹⁷ Duke Clinical Research Institute, Durham, Nortth Carolina, USA; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.
¹⁸ Cardiology. ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
¹⁹ Division of Cardiology, Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA.
²⁰ Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
²¹ Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan; Nara Prefecture Seiwa Medical Center, Sango, Japan.
²² Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
²³ Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan.
²⁴ University of Belgrade Faculty of Medicine, Serbian Academy of Sciences and Arts, and Heart Failure Center, Belgrade University Medical Center, Belgrade, Serbia.
²⁵ Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, California, USA.
²⁶ Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan.
²⁷ Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

PMID: 37117140
DOI: 10.1016/j.cardfail.2023.02.009

Abstract

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance. The present document is the result of the Trilateral Cooperation Project among the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America and the Japanese Heart Failure Society. It represents an expert consensus that aims to provide a comprehensive, up-to-date perspective on natriuretic peptides in the diagnosis and management of HF, with a focus on the following main issues: (1) history and basic research: discovery, production and cardiovascular protection; (2) diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy; (3) therapeutic use: nesiritide (BNP), carperitide (ANP) and ARNIs; and (4) gaps in knowledge and future directions.

Keywords: Heart failure, natriuretic peptides, diagnosis; therapy.

Publication types

Practice Guideline

MeSH terms

Biomarkers
Cardiology*
Heart Failure* / diagnosis
Heart Failure* / drug therapy
Heart Failure* / therapy
Humans
Natriuretic Peptide, Brain / therapeutic use
Natriuretic Peptides*
Peptide Fragments
Prognosis

Substances

Biomarkers
Natriuretic Peptide, Brain
Natriuretic Peptides
Peptide Fragments